Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February
Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras.
He takes the place of Longwood executive partner David Donabedian, who has taken the early CEO roles at a number of companies Longwood has backed, including Axial Therapeutics, ImmuneID and DEM BioPharma.
Vickers was previously head of Faze Medicines, a condensates biotech started by Third Rock that launched with $81 million in 2020 before shutting down at the end of last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.